|
General Partner, New Enterprise Associates
Dr. Barrett has served as a Director since December 2002 and as Chairman of the Board since January 2003. Dr. Barrett is a general partner of New Enterprise Associates (NEA), a venture capital management firm. He specializes in biotechnology and works with members of NEA's medical and life sciences investment group on medical devices, healthcare information systems and healthcare services companies. Dr. Barrett is currently on the boards of Cardioxyl Pharmaceuticals, CoGenesys, Inc., GlycoMimetics, Inc. Inhibitex, Macroflux Corporation, Nucleonics, Inc., Peptimmune, Pharmion Corporation, Ruxton Pharmaceuticals, Inc., Sensors for Medicine and Science, Supernus Pharmaceuticals, Inc. Targacept, YM Biosciences, and he formerly served on the board of MedImmune, Inc. purchased by AstraZeneca in June 2007. Prior to joining NEA in September 2001, Dr. Barrett served as Founder/Chairman/CEO of Sensors for Medicine and Science (1997 - 2001) where he remains Chairman. Prior to that, he was Chairman/CEO of Genetic Therapy (1987 - 1995), President/CEO of Life Technologies (1985 - 1987), and President/CEO of Bethesda Research Labs (1982 - 1983). Prior to 1982, Dr. Barrett worked in various divisions of SmithKline. Dr. Barrett received a Ph.D. in Biochemistry at the University of Tennessee, a Masters in Business Administration from the University of Santa Clara, and a Bachelor of Science in Chemistry from Boston College. | 